An HIV vaccine has successfully completed Phase I human clinical trials with 90 percent of volunteers developing an immunological response against the virus, reports. The MVA-B vaccine, researched by the Spanish Superior Scientific Research Council (CSIC), was carried out during a 48-week period and involved 30 healthy volunteers—24 were treated with MVA-B and six with a placebo. According to CSIC, “if this genetic cocktail passes Phase II and Phase III future clinic trials, and makes it into production, in the future HIV could be compared to herpes virus nowadays.” Phase 1 clinical trials will test MVA-B’s efficiency as a therapeutic vaccine.

To read the Gizmag article, click here.